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Abstract
Background: Cumulative genetic profiles can help identify individuals at high-risk for developing RA. We examined the
impact of 39 validated genetic risk alleles on the risk of RA phenotypes characterized by serologic and erosive status.
Methods/Principal Findings: We evaluated single nucleotide polymorphisms at 31 validated RA risk loci and 8 Human
Leukocyte Antigen alleles among 542 Caucasian RA cases and 551 Caucasian controls from Nurses’ Health Study and Nurses’
Health Study II. We created a weighted genetic risk score (GRS) and evaluated it as 7 ordinal groups using logistic regression
(adjusting for age and smoking) to assess the relationship between GRS group and odds of developing seronegative (RF2
and CCP2), seropositive (RF+ or CCP+), erosive, and seropositive, erosive RA phenotypes. In separate case only analyses, we
assessed the relationships between GRS and age of symptom onset. In 542 RA cases, 317 (58%) were seropositive, 163 (30%)
had erosions and 105 (19%) were seropositive with erosions. Comparing the highest GRS risk group to the median group,
we found an OR of 1.2 (95% CI=0.8–2.1) for seronegative RA, 3.0 (95% CI=1.9–4.7) for seropositive RA, 3.2 (95% CI=1.8–5.6)
for erosive RA, and 7.6 (95% CI=3.6–16.3) for seropositive, erosive RA. No significant relationship was seen between GRS
and age of onset.
Conclusions/Significance: Results suggest that seronegative and seropositive/erosive RA have different genetic
architecture and support the importance of considering RA phenotypes in RA genetic studies.
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Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflammatory
disease that often leads to disability from joint damage and
inflammation. Although RA is uncommon, with a worldwide
prevalence of approximately 1%, it has a large economic and
societal cost, primarily in terms of work-related disability [1]. Bony
destruction, or erosions, are associated with work disability [2] and
lower functional status [3,4] and thus with a more debilitating
disease phenotype. Before the more widespread use of biologics,
the incidence of erosions in RA patients was ,70% within the first
3 years after diagnosis [5]. However, with more advanced
treatment the prevalence of erosions has decreased [6,7].
Recently in genetic studies, RA has been divided into two
phenotypes defined by presence or absence of serologic factors.
Originally the subdivision was based on rheumatoid factor (RF),
but more recently antibodies to cyclic citrullinated proteins (anti-
CCP) have been used to define the two subtypes [8,9,10,11]. Both
RF and anti-CCP positivity have been linked to more severe
disease features and outcomes [12,13,14,15]. Presence of RF has
also been shown to be a major predictor of both development and
severity of joint erosions [16,17,18,19]. Based on these previous
results, we defined RA on a continuum of disease severity ranging
from seronegative RA (least severe phenotype) to seropositive RA
or erosive RA (more severe phenotypes) and finally to seropositive,
erosive RA (most severe phenotype).
In addition to erosions and serologic status, age at onset of
disease has been associated with RA outcomes, although the
results have been varied, with older disease onset predicting worse
outcomes in some [20,21,22,23] and milder outcomes in other
studies [22,24]. Specifically, Bukhari and colleagues showed that
those with older age of RA onset had higher odds of developing
erosive disease and a worse severity of erosions as compared to
those with onset ,50 years old [25]. Moreover, Pease et.al.
reported a slight increase in odds of erosions (although non-
significant) for those with onset 65 years or older, but in contrast
also found a 3 fold increase in odds of RA disease remission for the
same age group [22]. Earlier studies have also shown a lower
prevalence of HLA-DR4, the major genetic risk factor for RA, in
patients with later onset of RA, although not always significant
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have suggested that RA could potentially be divided into 2 subsets
defined by earlier versus later age at onset [22,26,27,28,30].
Methods
Objectives
Karlson et al. showed that a weighted Genetic Risk Score (GRS)
with 22 RA risk alleles showed a good discrimination between
seropositive RA and controls. The addition of a weighted GRS
score comprised of validated genetic risk factors showed improved
discrimination when compared to a model with just clinical risk
factors alone [31]. We extend this analysis in two ways, first,
by adding the newly validated RA risk alleles to the GRS
[32,33,34,35] and second, by assessing the GRS in relation to the
more specific phenotypes of RA along the severity continuum,
including erosive status, seropositivity and age at first symptom
onset of RA. We will show that the GRS is most applicable for the
more extreme RA phenotypes defined by seropositive and erosive
status, and consequently that these phenotypes have a different
genetic architecture than the seronegative and non-erosive forms
of the disease.
Participants
The Nurses’ Health Study is a prospective cohort which
enrolled 121,700 female nurses aged 30 to 55 years throughout the
US in 1976. Of those, 32,826 (27%) participants provided blood
samples for future studies and an additional 33,040 (27%)
provided buccal cell samples for a total of 65,866 (54%) samples
with available DNA. A similar prospective cohort, Nurses’ Health
Study II enrolled 116,609 female nurses aged 25 to 42 years in
1989, of which 29,611 (25%) provided blood samples for future
studies. For these analyses the two cohorts will be combined and
referred to as ‘NHS’.
Ethics
All aspects of this study were approved by the Partners Human
Research Committee, the Institutional Review Board of Partners
Research Management. Three types of written informed consent
were acquired for these studies. First, for questionnaires, NHS
cohort participants were consented by paper at baseline in 1976
for repeated surveys and NHSII cohort participants were
consented by paper at baseline in 1989 for repeated surveys.
Second, for the sub-cohorts who contributed blood for the genetic
analysis, the NHS participants were consented by paper in 1989 at
blood draw and the NHS2 participants were consented in 1997 at
blood draw. Finally, all RA self-reported cases signed informed
consent to release medical records for review.
Phenotypic Rheumatoid Arthritis
A staged screening method was used to confirm cases of RA in
the NHS cohort. A connective tissue disease (CTD) screening
questionnaire was used to screen all self-reported cases for RA
symptoms, followed by chart validation by two board-certified
rheumatologists [36]. Four phenotypes of RA were defined using
rheumatoid factor (RF) and/or CCP positivity and presence of
radiographic changes/erosions. Rheumatoid factor was deter-
mined by chart review. Second generation CCP assays were
performed among available pre-diagnosis or post-diagnosis blood
samples for a subset of cases (n=273 cases) as previously described
[37], all others were obtained by chart reviews since the mid-
2000’s when the test became widely available. Erosions were
determined by chart review [37]. The four RA phenotypes of
primary interest included: 1) seronegative RA (both RF and CCP
negative, n=225, in supplemental); 2) seropositive RA (either RF+
or CCP+ or both, n=317); 3) Erosive RA (presence of erosions,
n=163); and 4) seropositive, erosive RA (presence of erosions
AND in group 2, n=105). In addition, we also examined all RA
(n=542) and non-erosive RA (n=379) as a supplemental analysis.
The groups are not mutually exclusive, i.e. cases in the
seropositive, erosive RA group are also included in the seropositive
RA and the erosive RA groups. Age at RA onset was determined
from chart reviews as either age at onset of RA symptoms, if
available, or age at RA diagnosis.
Genotyping
Low resolution HLA-DRB1 genotyping was performed using
PCR with sequence-specific primers (SSP) using OLERUP SSP kits
(Qiagen,WestChester,Pennsylvania,USA),aspreviouslydescribed
[38]. For samples with positive two-digit human leucocyte antigen
(HLA) signals, SSP were used for high- resolution four-digit allele
detection of DRB1*0401, *0404, *0405, *0408, *0101, *0102, *09
and *1001. All non-MHC risk alleles were genotyped using iPlex
(Sequenom, San Diego, California, USA) at the Broad Institute, as
previously described [33]. All SNP had call rates greater than 95%
and Hardy–Weinberg equilibrium p values greater than 0.01.
Creation of Genetic Risk Score (GRS)
Thirty-nine validated risk alleles for RA are combined to form a
continuous GRS. This GRS is a weighted combination of 8 HLA-
DRB1 ‘shared epitope’ (HLA-SE) alleles and 31 non-MHC risk
alleles. Each allele is weighted by the natural log of the published
OR and then summed over 39 alleles, as previously described
[31,39,40]. Using a weighted risk score is important in this case
since both PTPN22 and the HLA-SE have a stronger predictive
relationship with RA as compared to the more recently discovered
SNPs. The list of alleles and weights are presented in Supplemen-
tal Table 1. We evaluated the linkage disequilibrium (LD)
structure of the risk alleles using HapMap release 22 and found
little evidence of LD (largest R
2=0.06) suggesting that LD has
little to no affect on the variance of the GRS.
The ORs and weights for the HLA-SE alleles are from a meta-
analysis of all published studies [41]. Odds ratios and weights for 5
out of the 31 non-MHC SNPs were taken from extensively
replicated SNPs from published studies. These include PTPN22
(rs2476601) [42], TRAF1-C5 (rs3761847) [43], STAT4 (rs7574865)
[44], TNFAIP3 (rs17066662, in LD with rs1099194, r
2=1.0) [45]
and TNFAIP3 (rs6920220) [45]. Odds ratios and weights for 9 of
the 31 non-MHC alleles were taken from a meta-analysis of
GWAS data for 3,393 cases and 12,462 controls with replication
in 3,929 seropositive RA cases and 5,807 matched controls by
Raychaudhuri et al, [33]. To avoid over-estimation of the true
effect size we used the ORs from the replication phase of the study
[32]. These SNPs include CD40 (rs4810485), CCL21 (rs2812378),
CTLA4 (rs3087243), PADI4 (rs2240340), CDK6 (rs42041),
TNFRSF14 (rs3890745), PRKCQ (rs4750316), KIF5A (rs1678542),
and 4q27 (IL2/IL21) (rs6822844) [33]. The ORs and weights for 7
risk alleles were selected from the joint analysis from Raychaud-
huri, et al [34] and were identified as functionally related to known
RA risk loci by GRAIL, a bioinformatics analysis that identifies
connections among genes in published abstracts. These include
PTPRC (rs10919563), CD2 (rs11586238), CD28 (rs1980422),
TAGAP (rs394581), RAG1 (rs540386), PRDM1 (rs548234), and
FCGR2A (rs7552317) [34]. Finally, 10 SNPs were selected from the
final combined analysis from a genome-wide association study
(GWAS) meta-analysis of 5,539 autoantibody positive RA cases
and 20,169 controls of European descent, followed by replication
in an independent set of 6,768 RA cases and 8,806 controls [35].
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C5orf13/GIN1 (rs26232), PXK (rs13315591), RBPJ (rs874040),
CCR6 (rs3093023), IRF5 (rs10488631), AAF3 (rs11676922),
CCL21 (rs951005) and IL2RA (rs706778).
The continuous GRS score was then divided into 7 sub-groups.
The thresholds for the groups were based on the Gaussian
distribution in the controls. A more detailed description of
methods is published elsewhere [31]. Briefly, dividing our score
into 7 categories provided the most robust distribution, allowing us
to parse out the highest and lowest risk groups while ensuring that
there were sufficient numbers of cases and controls in these
extreme categories of interest.
Study Sample Filtering
Each confirmed RA case was matched to one healthy control
by cohort (NHS or NHSII), year of birth, menopausal status, and
post-menopausal hormone use. Our initial nested case-control
dataset consisted of 585 RA cases and 585 matched controls. To
reduce the potential for population stratification we limited our
analysis to self-reported Caucasian women, resulting in 564 RA
cases and 571 controls. Since the HLA alleles have a large weight
in the GRS we dropped any participant missing HLA data.
Among the 564 RA cases, 22 (4%) were missing HLA, and
among the 571 healthy controls, 20 (4%) were missing HLA. This
left us with 542 RA cases and 551 healthy controls. For anyone
missing other SNPs, we assigned them a value equal to the
expected value (2*risk allele frequency defined in cases or controls
separately).
Epidemiological Covariates
Smoking is the strongest environmental factor linked with RA,
and its population attributable risk is 25% for all RA and 35% for
seropositive RA [46,47,48]. Prospective, biennial questionnaires
were used to collect covariate information from all NHS subjects.
The questions include inquiries regarding diseases, lifestyle and
health practices. Lifetime history of smoking was collected at the
baseline questionnaire and data concerning current smoking status
and number of cigarettes smoked per day were updated in each
two year questionnaire cycle. Pack-years were calculated as
number of packs per day smoked times number of years of
smoking using the questionnaire cycle prior to the date of RA
diagnosis or index date for matched controls.
Statistical Analysis
Demographic characteristics of the cohorts are described using
means and standard deviations for continuous variables and
frequency and proportions for categorical variables. Logistic
regression analysis was used to calculate the odds of a phenotypic
RA for each GRS risk group as compared to the median group
(group 4). The odds of phenotypic RA for the most extreme risk
group (group 7) as compared to the least extreme risk group (group
1) was calculated using an ordinal model that takes into account all
the data in all the groups. A test for linear trend across all seven
groups was performed using logistic regression, with each group
equaling the median GRS level in that group. The discriminatory
ability of the GRS to define case group vs. control group at
different combinations of sensitivity and specificity was assessed
using a Receiver Operating Characteristic (ROC) curve and
computing the Area Under Curve (AUC). Finally, Pearson
correlation coefficients were used to compare continuous GRS
and age at RA symptom onset and Analysis of Variance (ANOVA)
was used to calculate the mean age at RA symptom onset for each
GRS risk group. Models were adjusted for year of birth and pack-
years of smoking. All analyses were performed on SAS Version 9.1
(SAS Institute, Cary, NC).
Results
Subjects
Five hundred and forty two RA cases were identified with a
mean age at RA symptom onset of 56 (SD, 11). Of these, 317
(58%) were seropositive, 163 (30%) had evidence of erosions and
105 (19%) had seropositive, erosive RA. Five hundred and fifty-
one controls were selected among NHS participants who gave a
blood or buccal cell sample. The mean age at time of blood sample
was 55 (SD, 8) years for cases and 56 (SD, 8) years for controls.
Demographic information for cases and controls are presented in
Table 1.
Table 1. Characteristics of RA cases and controls in the Nurses’ Health Study.
RA cases (n=542) Controls (n=551)
Age, mean (SD)
a 55.3 (68.1) 55.5 (67.9)
Current or past smoker, n (%) 330 (62%) 309 (56%)
Pack-years among smokers, mean (SD) 25.0 (618.0) 22.7 (620.9)
RA features
Mean age at symptom onset, mean (SD) 55.7 (610.8) -
Mean age at diagnosis, mean (SD) 56.6 (610.2) -
Rheumatoid nodules, n (%) 70 (13%) -
Rheumatoid factor positive, n (%) 303 (56%) -
Anti-CCP
2 positive, n (%) 112 (34%) -
Seropositive, n (%) 317 (58%) -
Radiographic changes, erosions, n (%) 163 (30%) -
Seropositive and erosions, n (%) 105 (19%)
aAge at blood draw for blood samples (n=328 cases, n=334 controls),
2Cyclic citrullinated protein antibodies assayed in subset of NHS cases (n=327) with stored blood samples at collected at different points with respect to RA onset, up to
12 years prior to onset or after diagnosis.
doi:10.1371/journal.pone.0024380.t001
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Bivariate associations between single risk alleles and odds of
seropositive RA in the NHS data are presented in Supplemental
Table S1. In most cases the direction of the association in the NHS
data and the published ORs is the same, although most confidence
intervals cross the null value of 1.0. This is to be expected since the
individual effect sizes are small, and thus we do not have the power
to see significant bivariate associations.
GRS and Odds of Phenotypic RA
The results of the association analysis of three of the outcomes,
seropositive RA, erosive RA and seropositive, erosive RA are
presented in Table 2. The additional outcomes, all RA,
seronegative RA and non-erosive RA are presented in Supple-
mental Table S1. Group 4 (the median level of risk) was used as
the referent group in this analysis. Those with a GRS in group 7
had a significantly increased odds of seropositive RA (OR=3.0;
95%CI 1.9–4.7), erosive RA (OR=3.2; 95%CI 1.8–5.6) and
seropositive/erosive RA (OR=7.6; 95%CI 3.6–16.3), with the
highest increased odds being for seropositive/erosive RA. Those in
top GRS group (group 7) had no significant increase in odds of
seronegative RA (OR=1.2; 95%CI 0.8–2.1) (Supplementary
Table S2). The discrimination ability of the model, measured as
AUC, for predicting seronegative RA was 0.563, only slightly
above the null value of 0.50 (a null model would have an AUC of
0.500, whereas a perfect model would have an AUC of 1.0). The
other 3 phenotypes of RA showed better discrimination with
AUCs of 0.654, 0.644 and 0.712 for seropositive RA, erosive RA
and seropositive, erosive RA respectively. The ROC curves for 4
outcomes, seronegative, seropositive, erosive and seropositive,
erosive RA are represented in Figure 1. Since the outcomes vary
across the models we cannot directly compare the AUCs using the
known methods [49].
In the ordinal model, which takes into account all the data in all
the groups, we see a significant increase odds of seropositive RA
(OR=5.7; 95%CI 3.5–9.3), erosive RA (OR=4.9; 95%CI 3.2–
10.8) and seropositive/erosive RA (OR=14.2; 95%CI 6.5–30.9)
for group 7 as compared to group 1 (Table 2). In addition, we see
an increased odds of seronegative RA (OR=2.0; 95%CI 1.2–3.5)
for those with a GRS in the top group (group 7) compared to the
lowest risk group (group 1) (Supplementary Table S2). Strongly
significant linear trends were seen in the seropositive, erosive and
seropositive/erosive RA case groups, with all p-values,0.0001
(Table 2). For seronegative RA the p for trend was 0.007
(Supplementary Table S2).
Association between GRS and Age at RA Symptom Onset
The results for the association between the GRS and age at RA
symptom onset are presented in Table 3 and Supplementary
Table S3. The adjusted mean ages at RA symptom onset were not
significantly different among the 7 GRS groups for any of the
phenotype subgroups (p.0.05 for all). The correlations between
continuous GRS for seropositive RA, erosive RA and seropositive,
erosive RA all were negative (20.09, 20.08, 20.11 respectively)
indicating that the larger the GRS, the younger the age at first
symptom; however none of these correlations were significant.
Discussion
We found that a weighted genetic risk score was associated with
development of seropositive RA, erosive RA and seropositive,
erosive RA phenotypes. Although there was a significant linear
trend with a continuous GRS39 measure predicting seronegative
RA, with the exception of group 7 compared to group 1, there was
no significant relationship when the score was divided into groups.
In contrast, we found a strong and significant association between
both continuous and grouped GRS39 and the erosive and/or
seropositive phenotypes. Subjects with the highest GRS score
(group 7) had a 3.2 times increase of odds of erosive RA as
compared to the median group. This odds ratio increased to 7.6
when limiting the phenotype to those with seropositive, erosive
RA. We observed similar results when comparing extreme GRS
scores (group 7 vs. group 1), where we found a 5 times increased
odds of erosive RA and a 14 times increased odds for seropositive,
erosive RA. This suggests that the GRS has a stronger association
with the more severe phenotype; however narrowing the
phenotype definition resulted in a widened confidence interval.
Thus, although we detected a stronger effect size (i.e. larger OR),
there was also greater variability in the association, most likely due
to the small sample size in this group.
One interesting result is the association between the GRS with
39 risk alleles and seropositive RA. We found that group 7 had a
Table 2. Weighted GRS groups and odd ratios of seronegative, Seropositive, Erosive and Seropositive/Erosive RA in NHS.
GRS39 Group controls (n=551) Seropositive RA (n=317) Erosive RA (n=163) Sero+, Erosive RA (n=105)
n (%) n (%) OR
a (95% CI) n (%) OR
a (95% CI) n (%) OR
a (95% CI)
1 48 (9%) 11 (3%) 0.5 (0.2–1.1) 8 (5%) 0.7 (0.3–1.6) 4 (4%) 1.0 (0.3–3.2)
2 84 (15%) 17 (5%) 0.4 (0.2–0.8) 9 (6%) 0.4 (0.2–1.0) 2 (2%) 0.3 (0.1–1.3)
3 107 (19%) 57 (18%) 1.2 (0.7–1.8) 27 (17%) 1.0 (0.5–1.8) 19 (18%) 1.9 (0.8–4.3)
4 114 (21%) 55 (17%) 1.0 (ref) 28 (17%) 1.0 (ref) 10 (10%) 1.0 (ref)
5 84 (15%) 49 (15%) 1.3 (0.8–2.1) 23 (14%) 1.2 (0.6–2.2) 15 (14%) 2.2 (0.9–5.1)
6 50 (9%) 40 (13%) 1.7 (1.0–2.9) 19 (12%) 1.5 (0.8–3.0) 14 (13%) 3.4 (1.4–8.1)
7 64 (12%) 88 (28%) 3.0 (1.9–4.7) 49 (30%) 3.2 (1.8–5.6) 41 (39%) 7.6 (3.6–16.3)
p-value
b 1.7610
212 5.6610
29 5.0610
212
7 vs. 1
c 5.7 (3.5–9.3) 4.9 (3.2–10.8) 14.2 (6.5–30.9)
AUC AUC=0.654 AUC=0.644 AUC=0.712
aadjusted for year of birth and pack-years of smoking;
bfor linear trend, using an ordinal model;
cBased on an ordinal model.
doi:10.1371/journal.pone.0024380.t002
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4. This is similar to the 2.9 times increased odds found by Karlson
et al [31] with the GRS based on 22 risk alleles. In addition, we
observed a similar increase in ORs in the ordinal model when
comparing group 7 to group 1, where the OR was 6.3 (from
Karlson et al, with 22 risk alleles) and 5.7 in our analysis that
included 17 additional risk alleles. Similarly, the combination of
risk alleles also displayed a good ability to discriminate between an
RA case and control when the case is defined as seropositive RA,
erosive RA or seropositive, erosive RA. However, the GRS
showed very little, if any, ability to discriminate between
seronegative RA and controls with an AUC of 0.563. When we
compare the seropositive RA model with the 39 alleles to the one
from Karlson et al. with 22 alleles we see no improvement from
0.660 (GRS22) to 0.654 (GRS39). This suggests that the addition
of these 17 newly discovered RA alleles, whose individual ORs
range from 1.10 to 1.23, does not improve the predictive ability of
the GRS. As genetic discoveries progress with next generation
sequencing, it is likely that cumulative GRS will improve in its
predictive ability.
Our results for seronegative RA should be viewed in the context
of prior research. The loci used in the GRS were discovered and
Table 3. Relationship between weighted GRS as groups and as continuous and age at RA symptom start.
Mean Age
a (95% CI)
GRS39 Group Seropositive (n=317) Erosive RA (n=163) Sero+ Erosive RA (n=105)
1 51.1 (46.5–55.7) 52.3 (46.5–58.1) 42.3 (37.6–53.0)
2 57.4 (53.7–61.2) 55.1 (49.6– 60.6) 55.8 (44.8–66.8)
3 55.3 (53.2–57.4) 54.5 (51.2–57.8) 56.3 (52.6–60.1)
4 56.8 (54.7–58.9) 54.8 (51.7–58.0) 53.2 (48.1–58.2)
5 54.8 (52.6–57.0) 51.5 (48.0–55.0) 49.9 (45.7–54.1)
6 53.5 (51.0–56.0) 51.7 (47.8–55.6) 50.6 (46.5–54.8)
7 55.2 (53.5–56.8) 54.0 (51.6–56.3) 52.7 (50.2–55.2)
total 55.3 (54.1–56.4) 53.5 (51.9–55.2) 52.6 (50.6–54.5)
r
b 20.090 20.078 20.109
p-value 0.109 0.325 0.268
aadjusted for year of birth and pack-years of smoking,
br=Pearson correlation coefficient comparing continuous age at RA symptom onset and continuous GRS.
doi:10.1371/journal.pone.0024380.t003
Figure 1. Receiver Operating Characteristic (ROC) curve for 4 phenotypes of RA.
doi:10.1371/journal.pone.0024380.g001
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RA cases. Although there have been a few genetic markers that
have associated with an increase risk of seronegative RA, such as
HLA-DR1*03 [50], HLA-DR3 [51], and allelic forms of DCIR
[52] and IRF5 [53], there may be as yet undiscovered loci that
predict the seronegative RA phenotype. In a dataset containing
1500 cases/1500 controls, Kurreeman et al [54] demonstrated
that a GRS based on 28 non-HLA risk alleles was associated with
seronegative RA with an AUC of 0.55 and a p-value for a linear
association of 0.0008 also suggesting only a very modest
association for these risk alleles with the seronegative phenotype.
It has been shown that the HLA-SE is strongly associated with
both RF status and presence of anti-CCP antibodies [9,55,56].
More specifically, anti-CCP antibodies play a vital role in the
causal pathway between HLA-SE and erosions [29]. This is one
explanation of the results demonstrating that GRS39 performs
similarly when using erosive status to define severe disease, rather
than seropositivity. In addition, the observation of an AUC of
0.712 for GRS39 identifying seropositive, erosive RA cases
suggests that a narrower definition of RA leads to better
discriminative ability. This lends support to the argument that
RA falls along a severity continuum starting with seronegative as
least severe and leading to seropositive, erosive RA as most severe.
We found that earlier age at onset of RA may potentially be
associated with increased GRS. While the correlations were weak
and not statistically significant, this does suggest that perhaps those
with earlier age at RA onset have a higher ‘‘load’’ of genetic risk
factors than those with later onset. Previous studies have shown an
earlier age of diagnosis of RA both for those having any HLA-SE
compared to none [26,27,28], and for any PTPN22 T allele
compared to CCP [29]. Since both HLA and PTPN22 have a
strong influence on the GRS score, this may be one explanation
for the inverse relationship between the GRS and age at onset.
The strongest effects that we detected for GRS and age at onset
were with the seronegative and seropositive phenotypes. With this
number of subjects, we had 37% and 35% statistical power to
detect a significant r of 0.11 in seronegative and a r of 20.09 in
seropositive RA. It is possible with more subjects in all phenotype
groups we might have been able to detect significant relationships.
One limitation of our study is that we only have anti-CCP status
tested at one time point, either up to 12 years prior to time of RA
diagnosis or after diagnosis for the subset of cases without blood
sample collected. The lack of information for anti-CCP results in
the medical records due to the recent development of this test
limits our ability to study anti-CCP results after diagnosis in all
cases. We have not systematically collected outcome data after
diagnosis of RA in this cohort, thus we do not know if some of the
subjects defined as seronegative at diagnosis will later go on to
convert to seropositive. This could lead to misclassification bias,
with some truly seropositive RA subjects being misclassified as
seronegative, which would bias us away from the null in the
analysis. However, as we have found only modest associations
within the seronegative group we do not believe that this has
affected our analysis. This is also the case with erosive disease
status, which based on chart data included notes ranging from the
date of diagnosis where subjects have not had time to develop
erosions to many years of follow-up. Another possible limitation to
this study is the lack of data to test for population stratification.
However, a subset of this sample (437 RA cases and 437 controls)
[38] was genotyped for the lactase gene (rs4988235), known to
exhibit substantial variation in allele frequency from Northern to
Southern Europe [57,58]. No significant differences were found
between cases and controls, arguing strongly against any
significant population stratification in this dataset.
In summary, many arguments have been made in the last few
years for subdividing RA into different phenotypes [8,9,10,11].
The analyses here add credence to these arguments. We
demonstrate different genetic associations for the different RA
sub-types, with only a modest relationship seen in the least severe
phenotype, seronegative and the strongest relationship seen with
the most severe phenotype, seropositive, erosive RA. This suggests
that seropositive RA has a different underlying genetic basis than
seronegative RA and thus, in future research, studying the two
phenotypes separately would lead to greater understanding of the
genetic and functional make-up of the disease.
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